NEWS
ASH 2025 | Real-World Data on Injectable Aponermin Presented at ASH 2025
- Categories:Dynamic
- Author:医脉通血液科
- Origin:
- Time of issue:2025-12-26 10:56
- Views:
(Summary description)
ASH 2025 | Real-World Data on Injectable Aponermin Presented at ASH 2025
(Summary description)
- Categories:Dynamic
- Author:医脉通血液科
- Origin:
- Time of issue:2025-12-26 10:56
- Views:
During the 67th ASH Annual Meeting and Exposition held in Orlando, Florida, USA, from December 6–9, 2025, four poster presentations featuring injectable aponermin (brand name: 沙爱特®) were presented at the Orange County Convention Center, West Halls B3–B4.
PRESENTATION ID 2270
Safety and Efficacy of Aponermin-based Chemotherapy as Bridging therapy before CAR-T Cell Treatment in Relapsed/Refractory Multiple Myeloma
Huanxin Zhang1，Yi Wang2，Chengcheng Fu3，Yanli Feng2，Yang Liu1，Jing Wang3, Chunrui Li4，Wenming Chen5，ZhenYu Li1#
1.The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
2.Shaanxi Provincial People's Hospital, Xi’an, China
3.The First Affiliated Hospital of Soochow University, Suzhou, China
4.Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5.Beijing Chao Yang Hospital, Beijing, China
PRESENTATION ID 2271
Efficacy and Safety of Aponermin-Carfilzomib-Dexamethasone-based regimens for Relapsed/ Refractory Multiple Myeloma: A Phase 2 Prospective Multi-center Study
Huixing Zhou1, Chunrui Li2, Baijun Fang3, Lingzhi Yan4, Aijun Liu1, Peiling Zhang2, Yang Liu5, Xiaoqi Qin6, huanxin Zhang5, Wei Zhou7, Hong-hu Zhu1, Leng Yun1, Yin Wu1, Yi Wang7, Wenming Chen1, Guangzhong Yang1
1.Beijing Chao Yang Hospital.
2.Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
3.Henan Cancer Hospital.
4.The First Affiliated Hospital of Soochow University.
5.The Affiliated Hospital of Xuzhou Medical University.6.Second hospital of Shanxi Medical University. 7.Shaanxi Provincial People's Hospital.
PRESENTATION ID 2276
Aponermin Combined with Carfilzomib - Pomalidomide - Dexamethasone (KPd) in Patients with Relapsed or Refractory Multiple Myeloma: a Prospective, Open-Label, Multicenter Study
Jing Chen1, Donghua He1, Xiaoyan Han1, Mingming Zhang1, Li Yang1, Haimeng Yan1, Lai Jin2, He Huang1, Juan Du3, Aijun Liu4, Zhen Cai1
1.The First Affiliated Hospital, Zhejiang University, School of Medicine, Bone Marrow Transplantation Center, Hangzhou, Zhejiang, China
2.Zhejiang Provincial People’s Hospital, Hangzhou, China
3.Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China; Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
4.Beijing Chao. Yang Hospital, Capital Medical University, Beijing, China
PRESENTATION ID 2280
Phase 2 Study of Aponermin +KT-DECP in Patients with Relapsed/Refractory Multiple Myeloma and Extramedullary Disease
Menghan Liu1, Xiaoqi Qin2, Weiwei Tian3, Yuechen Zhang1, Yanru Zhang1, Lefu Huang1, Wenjing Li1, Jingrong Wang4, Yanping Ma2, Liping Su4, Yan Yan5, Aijun Liao6, Wenming Chen1, Aijun Liu1
1.Chao Yang Hospital Affiliated with Capital Medical University, Beijing, China
2.Second hospital of Shanxi Mecical University, Taiyuan, China
3.Shanxi Bethune Hospital, Taiyuan,China
4.Shanxi Cancer Hospital, Taiyuan, China
5.Bayannur Hospital, Bayannur, China
6.Shengjing Hospital of China Medical University, Shenyang, China
According to available statistics, a total of nine abstracts related to aponermin were accepted at ASH 2025, including four poster presentations. Based on the real-world data presented at this meeting, aponermin demonstrated encouraging efficacy when combined with multiple treatment regimens for multiple myeloma (MM), including patients with multi-line relapse, extramedullary plasmacytoma (EMP), high-risk cytogenetic features, and relapse after immunotherapy, with a manageable safety profile.
Scan the QR code to read on your phone
Copyright © 武汉海特生物制药股份有限公司 All Rights Reserved. 鄂ICP备05001864号-1 网站建设：中企动力 武汉
TOP